Enduring Response to Everolimus as Third-Line Therapy in a Patient With Advanced Renal Cell Carcinoma, Including Small-Bowel Metastases: Loss of FHIT but Normal VHL Gene Status

Enduring Response to Everolimus as Third-Line Therapy in a Patient With Advanced Renal Cell Carcinoma, Including Small-Bowel Metastases: Loss of FHIT but Normal VHL Gene Status

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Genitourinary Cancer - Volume 10, Issue 3, September 2012, Pages 202-206

Reuben J. Broom, Imogen Caldwell, Fritha Hanning, Peter Fong, Sanjeev Deva, Paul Oei,